Travoprost 0.004% gets Japan's approval

September 1, 2007

Japan's Ministry of Health, Labor, and Welfare has approved travoprost ophthalmic solution 0.004% (Travatan Z) for the treatment of glaucoma and ocular hypertension.

Tokyo-Japan's Ministry of Health, Labor, and Welfare has approved travoprost ophthalmic solution 0.004% (Travatan Z) for the treatment of glaucoma and ocular hypertension.

"Travoprost solution provides doctors with a new treatment option that may address an unmet need of many glaucoma patients-a prostaglandin analogue without benzalkonium chloride," Yoshiaki Kitazawa, MD, PhD, and director, Akasaka Kitazawa Eye Clinic, said in a prepared statement.

Japan has the distinction of having the world's second-largest population with glaucoma.